
Dr. Kunjahari Medhi is a senior Medical Oncologist and Haemato-Oncology specialist serving as Vice Chairman of Medical Oncology and Haemato-Oncology at Medanta – The Medicity, Gurugram. His clinical practice focuses on the diagnosis and treatment of solid tumours and blood-related malignancies in adult and paediatric patients.
He completed his DM in Medical Oncology from the All India Institute of Medical Sciences (AIIMS), New Delhi, in January 2007. He subsequently worked as a Senior Research Associate in Medical Oncology at AIIMS under the Council of Scientific and Industrial Research (CSIR). He also received advanced clinical research training at Oxford University, United Kingdom, through the INDOX Fellowship.
His clinical expertise includes chemotherapy, immunotherapy, targeted therapy, hormonal therapy and biological treatments for different malignancies. He also manages haematological cancers, including leukaemias and lymphomas, alongside solid tumour oncology and other complex cancer conditions.
Dr. Medhi has contributed to oncology research and clinical education through his academic work and professional training. He has also completed executive education in the advanced management of oncological diseases through Harvard Medical School, strengthening his background in modern cancer management and specialist oncology leadership.
Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Kunjahari Medhi for Hematology & BMT treatment in India.
Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Hematology & BMT in India.
Dr. Kunjahari Medhi regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.
Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.
World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.
Dr. Kunjahari Medhi holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in Hematology & BMT.
Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.
AML, CML, CLL, ALL, Hodgkin & Non-Hodgkin Lymphoma, Multiple Myeloma — treated with chemotherapy, targeted therapy & BMT.
Autologous, allogeneic, and haplo-identical BMT for leukemia, lymphoma, aplastic anemia, and inherited blood disorders.
Cutting-edge immunotherapy using genetically modified T-cells for blood cancers that have relapsed after standard treatments.
Curative BMT for thalassemia major and sickle cell anemia in children and adults. Low-cost programs available across India.
Both immunosuppressive therapy and stem cell transplantation for severe and very severe aplastic anemia, including pediatric cases.
HSCT (Hematopoietic Stem Cell Transplant) for aggressive Multiple Sclerosis — a disease-modifying treatment available in India.
Expert care for childhood leukemia, thalassemia, ITP, and inherited bone marrow failure syndromes.
Diagnosis and treatment of bone marrow failure and pre-leukemia syndromes with modern protocols.
Comprehensive management of hemophilia A & B, Von Willebrand disease, platelet disorders, and coagulopathies.
The most complex and potentially curative form of BMT where stem cells come from a matched donor. Used for leukemia, aplastic anemia, and inherited blood disorders.
Patient's own stem cells are harvested and reinfused after high-dose chemotherapy. Used for multiple myeloma and relapsed lymphomas.
Revolutionary immunotherapy where the patient's own T-cells are genetically reprogrammed to attack cancer cells.
The only curative treatment for beta-thalassemia major and sickle cell disease through allogeneic stem cell transplantation.
Personalised chemotherapy and next-generation targeted agents for lymphoma, leukaemia, and related disorders.
Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.
Our team responds within 24 hours
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.